Stockmarket

Biogen Price Targets Lowered Across the Board



© Reuters.

By Sam Boughedda

Investing.com — Several analysts cut their price targets on Biogen Inc’s (NASDAQ:) shares after concerns about Aduhelm sales following the company’s third quarter earnings report.

The biotechnology firm posted a revenue and EPS beat on Wednesday morning. Revenue came in at $2.78 billion, above the consensus of $2.67 billion, while its EPS was reported at $4.77, above the expected $4.11. 

However, it sold just $300,000 worth of its controversial Alzheimer’s drug Aduhelm, falling way short of analyst predictions. 

Oppenheimer analyst Jay Olson reduced the firm’s price target on Biogen to $390 from $450 but kept an outperform rating on the shares. Likewise, Cowen’s Phil Nadeau dropped his firm’s price target on Biogen to $375 from $450 with an outperform rating, as did RBC Capital analyst Brian Abrahams, who lowered the price target on Biogen to $295 from $325, and Piper Sandler analyst Christopher Raymond lowered Biogen’s price target to $390 from $460, keeping an overweight rating.

All four analysts cited the sales of Aduhelm as the reason for the price target decrease, with Piper Sandler’s Raymond stating that the Aduhelm launch was “even worse than feared.”

However, despite the downgrades, Biogen’s share price has remained resilient, up over 1.2% on Thursday, following Wednesday’s 0.58% decline. 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.